Oncology Nursing Society (ONS) Develops Evidence-Based Breast Cancer Chemotherapy and Survivorship Quality Measures

January 27, 2012

Kristen Fessele, RN, MSN, ANP-BC, AOCN Susan Beck, APRN, PhD, AOCN, FAAN Ellyn Matthews, RN, PhD, AOCN, CRNI Susan Yendro, RN, BSN Gail Mallory, PhD, RN, NEA-BC







Project Background

- Evidence-based practice (EBP) is a focus across all ONS activities
- Care practices on both the organization and clinician level must be guided by the highest-level of evidence available
- Evidence syntheses, clinical practice guidelines, comparative effectiveness research tell us what to do, but...







How well do clinicians implement the evidence where it matters?







© Copyright, The Joint Commission

How well does everyone implement the evidence where it matters?

- Ideally, a good quality measure is derived from a strong evidence base
- Focuses on a high-volume, high-impact process or outcome
- Is one that lends itself to a clear method of measurement







Project Overview

- The Oncology Nursing Society Foundation (ONSF) received a 3 year grant from the National Philanthropic Trust's Breast Cancer Fund
 - Develop and test quality measures
 - Facilitate incorporation of measures into existing quality measurement databases
 - Provide education on quality and quality measurement







5

Measure Sets

Developed and tested with

The Joint Commission's Dept. of Quality Measurement

• Based on ONS PEP resources and other sources

Breast Cancer Care (BCC)

 Focus on the care of patients receiving chemotherapy for breast cancer

Survivorship Quality Measures (BCS)

- Focus on the first year post-completion of treatment for early-stage breast cancer
- Visit <u>www.ons.org/Research/Quality</u> for more info

Breast Cancer Care (BCC)

Pre-treatment assessment

- Fatigue, Distress and Sleep-Wake Disturbance
- Continuing assessment
 - Same problems, assessed <u>every</u> cycle
- Intervention for clinically significant level of Distress or Sleep-Wake Disturbance
- **Exercise recommendation** made prior to chemo start
- Assessment of antiemetic regimen control
 - Before cycle 2 moderate to highly emetogenic chemo
- Hand washing and fever level to contact practice
- CSF prescribed for admin. 24-48h after myelosuppressive chemo







Breast Cancer Survivorship (BCS)

- Continued assessment of disease and treatment-related symptoms
- Interventions for clinically significant issues with assessed symptoms
- Education regarding:
 - Diet and exercise
 - S/S to report to provider
 - Resources available in the local community
 - Lymphedema risk reduction practices
- Individualized goal setting and attainment, with evidence of patient and family involvement (OUTCOME)
- Individualized follow up care recommendations for:
 - Bone density, breast imaging, LVEF monitoring, and pelvic exams where indicated
- Improvement of fatigue and distress scores over end-of-treatment baseline at 1 year follow up (OUTCOME)

Purpose of Pilot Testing

Refine measure specification language to stand alone "on the shelf"


Determine Reliability

- Measure Level
- Individual Data Elements
- Determine Burden Relative to Measure Set Implementation









Test Site Selection

- Wide geographic spread
- Mirror the universe of health care organizations "real world"
- Based on demographic characteristics
 - Practice size
 - Region (state)
 - Type of practice (organization, ownership)
 - Setting of Care (teaching/non-teaching, rural/suburban/urban)







Alpha Testing

- Establishes "basic" content validity
- Small focus group meetings at 4 pilot sites
 - Review language for each measure and associated data elements
 - -What do you think this is really asking you to find?
 - -Where would you find it in your records?
 - –How feasible would that be to do for multiple cases?
- Rank measures within set

Reliability Testing

- Re-abstraction site visits at 12 pilot sites
- Project staff abstract data on 20 cases
 - Adjudication software compares originally submitted data to staff collection
 - Mismatches immediately flagged
 - Staff interviews pilot site data collectors to uncover cause; frequently due to unclear specification language
- Data analysis provides adjusted scoring

UBCI	First Chemotherapy Date	CPT® Code	ICD-9-CM Diagnosis Code	Adjudication Report	Status 🚺
1	11-23-2010	96365	1741	Finished	
987654	51-36-8496	96360	8997*/	Finished	
Cycle1	07-01-2009	96413	1759	🖆 Adjudicate	▼ 1
Age 18 Sex Assess Assess Assess Re-Ass Interven Re-Ass Sleep-V Interven Re-Ass Exercis Reasor Emetog Assess Vomitin Myelosu Instructi Instructi	ment for Distress ment for Fatigue ment for Sleep-Wake essment for Distress s ntion for Distress essment for Sleep-W Vake Disturbance tion for Sleep-Wake I essment for Fatigue e Program n for Not Recommend penic Agents ment for Chemothera a	Disturbance ake Disturbance Disturbance ling Exercise apy Induced Nau erapy		2 4 Y	



General and other pa	tient-level data elements			
Field Name		Congruence	Adjudicati	tion
Unique Blinded Case Identifier		Yes	-	
First Chemotherapy Date		No	DONE	
Original Value 2: 11-23-4889 Abstracted Value: 11-23-2010 Adjudicated Value: 2 Post adjudicated value Reason: Data entry error				
	Select Specifications Misinterpreted or Not Followed Data entry error Missing Data Conflicting information in record Other			
CPT® Code	Skip logic issue - no abstraction required	Yes	-	
ICD-9-CM Diagnos	Different Data Source Used	Yes	-	
Age 18 or Greater		No	DONE	
Sex	Sex		-	
Assessment for Dis	stress	Yes	-	
Assessment for Fa	tigue	Yes	-	
Assessment for Sleep-Wake Disturbance		Yes	-	
Re-Assessment for	Re-Assessment for Distress		-	
Distress		No	DONE	
Intervention for Distress		Yes	-	
De Assessed for Oleve Melle Disfusiones				

Reliability Findings

- Good agreement on:
 - Demographics
 - Lack of exercise recommendations
- Most mismatches related to:
 - Definition of distress
 - Lack of documentation of symptom intensity
 - Identification of myelosuppressive regimens
 - Need to evaluate all cycles in the continuing assessment measures (BCC-02)







Selected BCC testing results

- Exercise not often recommended
- Sleep-Wake disturbance not commonly assessed
- Symptom assessment by nursing varies
 - Charting by exception
 - SOAP note format
 - Symptom intensity not commonly
 - documented







Pilot Data Summary

Measure ID	Measure Name	Denominator for Pilot Study	Rate for Pilot Study
BCC-01a	Pre-treatment Assessment – Overall Rate	1076	33.27%
BCC-01b	Pre-treatment Assessment – Distress	1076	75.93%
BCC-01c	Pre-treatment Assessment – Fatigue	1076	64.50%
BCC-01d	Pre-treatment Assessment – Sleep-Wake Disturbance	1076	37.17%
BCC-02a	Continuing Assessment – Overall Rate	1073	19.85%
BCC-02b	Continuing Assessment – Distress	1073	55.55%
BCC-02c	Continuing Assessment – Fatigue	1073	62.07%
BCC-02d	Continuing Assessment – Sleep-Wake Disturbance	1073	27.03%
BCC-03	Intervention for Distress	697	32.14%
BCC-04	Intervention for Fatigue	1072	9.79%
BCC-05	Intervention for Sleep-Wake Disturbance	809	12.36%
BCC-06	Assessment for Chemo-Induced Nausea and Vomiting	961	87.41%
BCC-07	Education on Neutropenia Precautions	851	55.82%
BCC-08	Colony Stimulation Factors (CSF) Prescribed	4276	12.36% 87.41% 55.82% 76.26%








© Copyright, The Joint Commission

Pilot Data Summary









Pilot Site Feedback

- Overall, measure set is meaningful
- Clarification of what distress includes, and how it is measured in practice needed
- Clarification of which regimens are considered myelosuppressive
- More specific guidelines for exercise recommendations
- More examples in Notes for Abstraction







Oncology Quality Collaborative (OQC)

- Implementation work group
- Community of Practice model
- First session of OQC limited to interested BCC pilot site participants
 - 15 sites opted in
- Focus on evidence-based practice changes needed to increase QM scoring
 - Symptom Assessment
 - Exercise Recommendations









Breast Cancer original focus in deference to funder

- National Philanthropic Trust's Breast Cancer Fund
- Many measures easily applied to other disease states
- Opportunities to develop many additional sets based on existing strong evidence







Summary

- High-level evidence supports creation of meaningful quality measures
 - How consistently are we implementing our best knowledge?
- Nationally tested measures based on PEP resources allow benchmarking of nurse-sensitive interventions across diverse sites
- QM are one important link in a chain of evidence translation and implementation
- Nurses are well-positioned to drive "Patientcenteredness" and high-quality cancer care!

Partial List of Pilot Sites

- Central Vermont Medical Center; Mountainview Medical, Berlin, VT
- CR Wood Cancer Center, Glens Falls, NY
- The Cancer Institute of New Jersey, New Brunswick, NJ
- Edwards Cancer Centers, Napierville, IL
- Fairfax Northern Virginia Hematology Oncology, Fairfax, VA
- Froedtert Hospital and the Medical College of WI, Milwaukee, WI
- Group Health, Seattle, WA
- Lankenau Hospital, Wynnewood, PA
- Magee Womens Hospital of University of Pittsburgh Cancer Centers, Pittsburgh, PA
- Norton Cancer Institute, Louisville, KY
- Our Lady of Bellefonte Hospital (The Women's Center), Ashland, KY
- Saint Joseph's Hospital, Nashua, NH
- Seidman Cancer Center, Cleveland, OH
- University Of Miami, Miami, FL
- Southwestern Vermont Regional Cancer Center, Bennington, VT

Co-Authors/Team Members



Susan Beck, APRN, PhD, AOCN, FAAN



Ellyn Matthews, RN, PhD, AOCN, CRNI







Gail Mallory, PhD, RN, NEA-BC



Susan Yendro, RN, BSN



Questions? kfessele@ons.org









© Copyright, The Joint Commission